Skip to main content

Advertisement

Table 4 Univariate analyses of factors associated with severe and/or opportunistic infections. Landmark competing risk analysis at 9 months. sHR indicates sub-Hazard Ratio

From: Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia

  Infections Relapse/death
Variables sHR [95%CI] p sHR [95%CI] p
EOT MRD status (n = 125)
  < 10−4 (ref) 1.00   1.00  
  ≥ 10−4 0.72 [0.29; 1.82] 0.492 3.02 [1.68; 5.45] < 0.001
EOT CD4 (/mm3, n = 125)
  ≤ 200 (ref) 1.00   1.00  
  > 200 0.97 [0.40; 2.38] 0.948 2.34 [1.26; 4.33] 0.007
EOT NK (/mm3, n = 119)
  ≤ 100 (ref) 1.00   1.00  
  > 100 0.51 [0.21; 1.22] 0.128 1.07 [0.58; 1.96] 0.837
EOT CD8 (/mm3, n = 125)
  ≤ 150 1.00   1.00  
  > 150 1.84 [0.79; 4.30] 0.158 1.06 [0.59; 1.89] 0.843